1-5 of 5
Michele Kosh
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Monumental-6: A Phase 3 Study of Talquetamab + Pomalidomide or Talquetamab + Teclistamab Vs Elotuzumab + Pomalidomide + Dexamethasone (EPd) or Pomalidomide + Bortezomib + Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma Who Received 1-4 Prior Lines of Therapy, Including Lenalidomide and an Anti-CD38 Monoclonal Antibody

Ajay K. Nooka, Hira Mian, Cindy Lee, Paula Rodríguez-Otero, Shaji Kumar, Hermann Einsele, Deeksha Vishwamitra, Diego Vieyra, Colleen Kane, Michele Kosh, Tara J Masterson, Christoph Heuck, Ankit Kansagra, Philippe Moreau
Journal: Blood
Blood (2024) 144 (Supplement 1): 4757.1.
https://doi.org/10.1182/blood-2024-199752
Published: 2024
Journal Articles

Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 Apollo Study

Meletios A. Dimopoulos, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksac, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena Bila, Albert Oriol, Maria-Victoria Mateos, Hermann Einsele, Ioannis Orfanidis, Tobias Kampfenkel, Weiping Liu, Michele Kosh, NamPhuong Tran, Robin Carson, Pieter Sonneveld
Journal: Blood
Blood (2022) 140 (Supplement 1): 7272–7274.
https://doi.org/10.1182/blood-2022-163483
Published: 2022
Journal Articles

Pomalidomide and Dexamethasone with or without Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Updated Analysis of the Phase 3 Apollo Study

Pieter Sonneveld, Evangelos Terpos, Mario Boccadoro, Sosana Delimpasi, Meral Beksac, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena Bila, Albert Oriol, Maria-Victoria Mateos, Hermann Einsele, Ioannis Orfanidis, Tobias Kampfenkel, Yanping Qiu, Himal Amin, Michele Kosh, NamPhuong Tran, Robin Carson, Meletios A. Dimopoulos
Journal: Blood
Blood (2021) 138 (Supplement 1): 2747.
https://doi.org/10.1182/blood-2021-146907
Published: 2021
Journal Articles

Subcutaneous Daratumumab (DARA SC) Plus Standard-of-Care (SoC) Regimens in Multiple Myeloma (MM) across Lines of Therapy in the Phase 2 Pleiades Study: Initial Results of the Dara SC Plus Carfilzomib/Dexamethasone (D-Kd) Cohort, and Updated Results for the Dara SC Plus Bortezomib/Melphalan/Prednisone (D-VMP) and Dara SC Plus Lenalidomide/Dexamethasone (D-Rd) Cohorts

Philippe Moreau, MD, Ajai Chari, Mathias Haenel, MD, Albert Oriol, Paula Rodriguez-Otero, MD PhD, Helen McCarthy, PhD FRCPath, Kenshi Suzuki, MD PhD, Vania T. M. Hungria, MD PhD, Anna Sureda Balari, MD PhD, Lauriane Clement-Filliatre, MD, Cyrille Hulin, MD, Hila Magen, MD, Shinsuke Iida, MD PhD, Vladimir Maisnar, MD, Lionel Karlin, MD, Luděk Pour, MD, Cyrille Touzeau, Shiyi Yang, Michele Kosh, Maria Delioukina, Christoph Heuck, Hartmut Goldschmidt, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–30.
https://doi.org/10.1182/blood-2020-134935
Published: 2020
Journal Articles

Subcutaneous Daratumumab Plus Standard Treatment Regimens in Patients with Multiple Myeloma across Lines of Therapy: Pleiades Study Update

Ajai Chari, MD, Jesús San-Miguel, Helen McCarthy, MBBS, PhD, Kenshi Suzuki, MD PhD, Vania T.M. Hungria, MD PhD, Anna Sureda, MD PhD, Aurore Perrot, MD PhD, Cyrille Hulin, MD, Hila Magen, MD, Shinsuke Iida, MD PhD, Vladimir Maisnar, MD PhD MBA, Lionel Karlin, MD, Ludek Pour, MD, Dolly A. Parasrampuria, PhD, Tara Masterson, Michele Kosh, RN, BSN, Shiyi Yang, Maria L. Delioukina, MD, Ming Qi, MD PhD, Robin Carson, MD BA, Cyrille Touzeau, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 3152.
https://doi.org/10.1182/blood-2019-123560
Published: 2019